RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous treatment. A fundamental histological transformation from NSCLC to small-cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Niederst, Matthew J., Sequist, Lecia V., Poirier, John T., Mermel, Craig H., Lockerman, Elizabeth L., Garcia, Angel R., Katayama, Ryohei, Costa, Carlotta, Ross, Kenneth N., Moran, Teresa, Howe, Emily, Fulton, Linnea E., Mulvey, Hillary E., Bernardo, Lindsay A., Mohamoud, Farhiya, Miyoshi, Norikatsu, VanderLaan, Paul A., Costa, Daniel B., Jänne, Pasi A., Borger, Darrell R., Ramaswamy, Sridhar, Shioda, Toshi, Iafrate, Anthony J., Getz, Gad, Rudin, Charles M., Mino-Kenudson, Mari, Engelman, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Pub. Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357281/
https://www.ncbi.nlm.nih.gov/pubmed/25758528
http://dx.doi.org/10.1038/ncomms7377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357281/
https://www.ncbi.nlm.nih.gov/pubmed/25758528
http://dx.doi.org/10.1038/ncomms7377

Ejemplares similares